Print this page
Sarcoma
-
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial).
Protocol: 022404-MM1YA-CTGPrincipal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm.
Protocol: 032006Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score less than or equal to 25 (OFSET).
Protocol: 042313Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants with HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer.
Protocol: 042412Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.
Protocol: 052410Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Heptocellular Carcinoma and CHILDPUGH B7 and B8 Cirrhosis.
Protocol: 072309Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Liver -
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer.
Protocol: 072405Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of
Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab
as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Protocol: 072502Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Liver -
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer.
Protocol: 082401Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684 Based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Protocol: 082408Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer.
Protocol: 082501Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
A032201: Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-risk renal cell carcinoma STRIKE
Protocol: 082502Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2).
Protocol: 092401Principal Investigator:
- Vadim Koshenkov
Applicable Disease Sites: Soft Tissue -
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma.
Protocol: 092402Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin
- 1
- 2